Quantitive immunohistochemical analysis based on the percentage of TSG101-immunopositive cells revealed a significantly (P<0.05) lower percentage of TSG101-immunopositive cells in cervical cancer and HSIL samples compared with that in non-tumor (HPV-negative) cells (Fig. 1A). This evidence concerns the gene TSG101 and cervical carcinoma.